Ortec International
This article was originally published in The Gray Sheet
Executive Summary
Investigational device exemption is submitted to FDA to begin clinical trials of its CCS composite cultured skin for the treatment of diabetic ulcers. The multi-center study is expected to involve approximately 32 patients to be followed for up to six months